Affordable Access

deepdyve-link
Publisher Website

Persistent suppression of ocular neovascularization with intravitreal administration of AAVrh.10 coding for bevacizumab.

Authors
  • Mao, Yanxiong1
  • Kiss, Szilard
  • Boyer, Julie L
  • Hackett, Neil R
  • Qiu, Jianping
  • Carbone, Andrew
  • Mezey, Jason G
  • Kaminsky, Stephen M
  • D'Amico, Donald J
  • Crystal, Ronald G
  • 1 Department of Respiratory Medicine, West China Hospital, Sichuan University, Sichuan 610041, China. , (China)
Type
Published Article
Journal
Human Gene Therapy
Publisher
Mary Ann Liebert
Publication Date
December 2011
Volume
22
Issue
12
Pages
1525–1535
Identifiers
DOI: 10.1089/hum.2011.090
PMID: 21801028
Source
Medline
License
Unknown

Abstract

Vascular endothelial growth factor (VEGF) plays an important role in the pathogenesis of neovascular age-related macular degeneration and diabetic retinopathy. Bevacizumab, an anti-VEGF monoclonal antibody, is efficacious for these disorders, but requires monthly intravitreal administration, with associated discomfort, cost, and adverse event risk. We hypothesized that a single intravitreal administration of adeno-associated virus (AAV) vector expressing bevacizumab would result in persistent eye expression of bevacizumab and suppress VEGF-induced retinal neovascularization. We constructed an AAV rhesus serotype rh.10 vector to deliver bevacizumab (AAVrh.10BevMab) and assessed its ability to suppress neovascularization in transgenic mice overexpressing human VEGF165 in photoreceptors. Intravitreal AAVrh.10BevMab directed long-term bevacizumab expression in the retinal pigmented epithelium. Treated homozygous mice had reduced levels of neovascularization, with 90±4% reduction 168 days following treatment. Thus, a single administration of AAVrh.10BevMab provides long-term suppression of neovascularization without the costs and risks associated with the multiple administrations required for the current conventional bevacizumab monoclonal drug delivery.

Report this publication

Statistics

Seen <100 times